HPV in Women: The Leading Cause of Cervical Cancer

Human papillomavirus, better known as HPV, is extremely common. So common, in fact, that encountering HPV during a sexually active lifetime is less like being struck by lightning and more like eventually receiving a spam email. Most infections disappear without causing trouble, but persistent infection with certain high-risk HPV types can lead to cervical cancer.

HPV causes virtually all cervical cancers. That sounds alarming, but it also reveals an important opportunity: because researchers know what drives the disease, cervical cancer can often be prevented through HPV vaccination, routine screening, and timely treatment of precancerous cervical changes.

This article focuses on HPV in women, although the screening information generally applies to anyone with a cervix. It explains how HPV spreads, why only some infections become dangerous, what test results mean, and how women can protect their health without panic or stigma.

What Is HPV?

HPV is a family of more than 200 related viruses. Some infect the skin, while others prefer mucous membranes in areas such as the cervix, vagina, vulva, anus, penis, mouth, and throat.

Genital HPV usually spreads through intimate skin-to-skin contact, including vaginal, anal, and oral sex. Penetration is not required for transmission, and a person can pass HPV without having symptoms, visible warts, or any idea that the infection is present.

Low-risk and high-risk HPV types

Health professionals generally divide genital HPV types into two broad groups:

• Low-risk HPV: These types may cause genital warts but are not responsible for cervical cancer. HPV types 6 and 11 cause most genital warts.
• High-risk HPV: Persistent infection with these types can cause abnormal cellular changes and several cancers. HPV types 16 and 18 account for roughly 70% of cervical cancers worldwide.

Genital warts are therefore not an early stage of cervical cancer. The HPV types that usually produce warts differ from the types most likely to produce cancer. They belong to the same large viral family, but they are very different houseguests.

How HPV Can Become Cervical Cancer

The cervix is the lower, narrow portion of the uterus that opens into the vagina. Its surface contains cells that can become infected with high-risk HPV.

About nine out of ten HPV infections clear or become undetectable within two years as the immune system controls them. A brief infection does not normally cause cancer. The concern is an infection with a high-risk type that remains active for years.

From infection to precancer

Persistent high-risk HPV can interfere with the normal controls governing cervical cell growth. Over time, infected cells may develop abnormal changes known as cervical dysplasia or cervical intraepithelial neoplasia, commonly abbreviated as CIN.

CIN is not cervical cancer. Mild abnormalities often resolve without treatment, especially in younger women. More serious changes, such as CIN 2 or CIN 3, carry a greater risk of progressing and may need to be removed or destroyed.

The progression generally follows this pattern:

1. A high-risk HPV type infects cervical cells.
2. The immune system either clears the infection or the infection persists.
3. Persistent infection may produce low-grade or high-grade cell changes.
4. Untreated high-grade abnormalities can eventually become invasive cervical cancer.

This process usually takes years rather than weeks. That slow development creates a valuable window in which screening can find and treat precancer before it becomes dangerous.

Who Is More Likely to Develop Cervical Cancer?

Exposure to HPV is common and is not evidence of irresponsible behavior. Having more sexual partners, or having a partner with multiple previous partners, can increase the opportunity for exposure. However, one lifetime partner is enough to acquire HPV.

Factors that make persistent infection or cervical cancer more likely include:

• Smoking or regular exposure to tobacco products
• HIV or another condition that weakens the immune system
• Medicines that suppress immunity after transplantation or during treatment of certain illnesses
• A history of high-grade cervical precancer
• Infrequent screening or failure to complete follow-up after an abnormal result
• Exposure before birth to diethylstilbestrol, or DES

Health care access matters, too. Women without adequate insurance, transportation, paid time off, or nearby clinics are more likely to be underscreened. Cervical cancer prevention is partly a medical challenge and partly an access challenge.

Does HPV Cause Symptoms in Women?

High-risk cervical HPV usually causes no symptoms. A woman may feel completely healthy while the infection or early cell changes are present. There is also no routine blood test that tells someone whether she has cervical HPV.

Low-risk types may cause genital warts. These can appear as flat spots, small bumps, or clustered cauliflower-like growths around the vulva, vagina, cervix, or anus. Warts may itch or feel tender, although they are frequently painless.

Possible cervical cancer warning signs

Early cervical cancer may also be silent. As it grows, possible symptoms include:

• Bleeding after sexual intercourse
• Bleeding between menstrual periods
• Any vaginal bleeding after menopause
• Periods that become unusually heavy or prolonged
• Persistent watery, bloody, or strong-smelling vaginal discharge
• Pelvic pain or pain during sex

Advanced disease can cause back pain, leg swelling, fatigue, weight loss, or urinary and bowel symptoms. These problems have many possible explanations and do not automatically mean cancer. Nevertheless, unusual bleeding or persistent pelvic symptoms deserve prompt medical evaluation. A screening schedule is intended for people without symptoms; symptoms require diagnostic care rather than waiting for the next routine test.

HPV Tests, Pap Tests, and Current Screening Options

People often use “Pap test” and “HPV test” as if they were interchangeable. They are related, but they look for different things:

• An HPV test detects high-risk HPV types associated with cervical precancer and cancer.
• A Pap test, also called cervical cytology, looks for abnormal cervical cells.
• Co-testing performs both tests on a clinician-collected cervical sample.

A pelvic examination alone is not a cervical cancer screening test. Likewise, most routine sexually transmitted infection panels do not automatically include HPV testing.

How often should women be screened?

U.S. recommendations differ slightly among professional organizations, so women may encounter more than one valid schedule. Under updated Women’s Preventive Services Initiative guidance endorsed by the American College of Obstetricians and Gynecologists for average-risk patients:

• Ages 21 to 29: Cervical cytology alone every three years.
• Ages 30 to 65: Clinician-collected primary high-risk HPV testing every five years is preferred. Co-testing every five years is another option. If high-risk HPV testing is unavailable, cytology alone every three years remains acceptable.
• After age 65: Screening may stop after adequate negative prior screening and no significant history of cervical precancer or cancer. Age alone should not make that decision.

The American Cancer Society uses a somewhat different average-risk guideline, beginning screening at age 25 and favoring primary HPV testing. Because guidelines evolve and personal histories vary, a clinician should confirm which schedule applies to an individual patient.

Women with HIV, immune suppression, previous cervical cancer, significant precancer, abnormal prior results, or prenatal DES exposure may need a different plan. Screening may also remain necessary after a hysterectomy if the cervix was not removed or if surgery was related to cervical precancer or cancer.

What about self-collected HPV testing?

FDA-authorized self-collection has expanded screening choices. Certain tests allow an eligible patient to collect a vaginal sample with a swab, either in an approved health care setting or, for a specific authorized system, at home after a health professional orders the test.

Self-collection can help women who have avoided screening because of discomfort, trauma, disability, privacy concerns, or limited access to a clinician. It is intended for routine screening in eligible, average-risk patientsnot for evaluating abnormal bleeding or following a previous abnormal result. A positive self-collected result may also require a clinician-collected cervical sample and additional testing.

What Does a Positive HPV Test Mean?

A positive high-risk HPV test means that a cancer-associated HPV type was detected. It does not mean cervical cancer is present. It also cannot reveal exactly when the infection began or who transmitted it.

HPV can remain quiet or undetectable for years and later become detectable again. Consequently, a positive result in a long-term relationship is not proof of recent sexual contact or infidelity. Viruses are notoriously bad at supplying timestamps.

Follow-up depends on the HPV type, Pap findings, age, previous results, and treatment history. A clinician may recommend:

• Repeating HPV or co-testing after a defined interval
• Testing specifically for HPV 16, HPV 18, or other high-risk groups
• Colposcopy, which uses magnification to examine the cervix
• A cervical biopsy
• Treatment for confirmed high-grade precancer

There is no medication that simply erases HPV from the body. Treatment instead targets problems caused by the virus, such as genital warts or abnormal cervical tissue. The most important step after a positive result is completing the recommended follow-up.

How Women Can Reduce Their Risk

Get vaccinated when eligible

Gardasil 9 protects against nine HPV types, including seven associated with cancer and two responsible for most genital warts. Vaccination prevents new infections; it does not treat an existing infection.

Routine vaccination is recommended at ages 11 or 12 and may begin at age 9. Catch-up vaccination is recommended through age 26 for those who were not fully vaccinated. Adults ages 27 through 45 may consider vaccination through shared decision-making with a health care professional.

People who start the series before age 15 generally receive two doses six to twelve months apart. Those starting at 15 or older usually receive three doses. Immunocompromised people also generally need a three-dose series. Someone who has already had one HPV type may still gain protection against other vaccine-covered types.

Keep screening even after vaccination

The vaccine offers powerful protection, but it does not cover every cancer-associated HPV type. Vaccinated women should therefore continue cervical screening according to the schedule appropriate for them.

Use barriers and avoid tobacco

Condoms and dental dams reduce HPV transmission but cannot eliminate it because uncovered skin can carry the virus. They still provide valuable protection against HPV and other sexually transmitted infections.

Not smoking is another meaningful preventive step. Tobacco can impair local immune defenses and make it harder for the body to control an HPV infection. Women who smoke can ask a clinician about counseling, nicotine replacement, or prescription cessation treatments.

Experiences Women Commonly Have With HPV

The following examples are fictional composites based on common concerns reported in clinical education and patient care. They do not describe identifiable individuals.

The unexpected positive result

At 34, “Maya” expected her routine appointment to be gloriously uneventful. Her high-risk HPV result came back positive even though she had been with the same partner for eight years. Her first reaction was fear; her second was suspicion. She wondered whether the result meant cancer or recent infidelity.

Her clinician explained that neither conclusion was justified. HPV can be acquired years earlier, become undetectable, and later appear on a test. Maya’s Pap result showed no abnormal cells, so her next step was repeat testing at the interval her clinician recommendednot chemotherapy, surgery, or an emergency confrontation over dinner. Understanding the result changed it from a verdict into a follow-up task.

The abnormal Pap that was not cancer

“Erin,” 27, saw the phrase “abnormal squamous cells” in her online chart before anyone called her. Naturally, she consulted the internet, which responded with its usual bedside manner: everything might be catastrophic.

Follow-up testing found a low-grade change associated with HPV. Her clinician explained that mild abnormalities commonly regress, particularly in younger adults, and that surveillance was safer than rushing into unnecessary treatment. Later testing returned to normal. Erin’s experience illustrates why an abnormal Pap result should be taken seriously without being interpreted as a cancer diagnosis.

The screening appointment postponed for years

“Danielle” avoided cervical screening because a previous pelvic examination had been painful and emotionally difficult. Every reminder produced the same promise: perhaps next month. When her clinic began offering patient-collected HPV testing to eligible patients, she discussed the option with a clinician and completed a self-collected test privately.

The result was negative, and she left with a clear plan for future screening. Self-collection did not make every gynecologic concern disappear, but it removed one barrier that had kept her entirely outside preventive care. For many women, a technically available test becomes useful only when it is also tolerable and accessible.

The importance of finishing follow-up

“Rosa” received an abnormal result but delayed colposcopy because she lacked paid leave and worried about the cost. A patient navigator helped her find a covered clinic appointment and transportation assistance. The biopsy identified high-grade precancer, which was treated before invasive cancer developed.

Her story highlights a frequently overlooked truth: screening is not complete when the laboratory posts a result. Prevention depends on communicating that result, arranging appropriate evaluation, and completing recommended treatment. Women who face financial, language, transportation, disability, or scheduling barriers should tell the clinic. Community health centers and public screening programs may be able to help.

Across these experiences, the recurring lesson is reassuringly practical. HPV is common, a positive test is not a moral judgment, and an abnormal result is not automatically cancer. The safest response is to understand the specific finding, ask what happens next, and put the follow-up date somewhere harder to ignore than the bottom of an email inbox.

Conclusion

Persistent high-risk HPV is the cause of virtually all cervical cancers, yet most HPV infections never become cancer. Vaccination can prevent the most dangerous infections, while HPV and Pap testing can identify risk or precancerous changes years before invasive disease develops.

Women should know their vaccination history, follow an appropriate screening schedule, and complete every recommended follow-up. They should also seek medical care for unusual bleeding, persistent discharge, pelvic pain, or pain during sex rather than waiting for routine screening. Cervical cancer remains serious, but it is also one of the cancers for which prevention can make an extraordinary difference.